Individualised measures of performance ‐ not measured · children with unilateral cerebral palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with unilateral cerebral palsy
1 finding from 1 review
Manual ability ‐ not measured · children with unilateral cerebral palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐care ‐ not measured · children with unilateral cerebral palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Individualised measures of performance ‐ not measured · children with unilateral cerebral palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with unilateral cerebral palsy
1 finding from 1 review
Bimanual performance · children with unilateral cerebral palsy
1 finding from 1 review
Functional impairment · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
2 findings from 1 review
Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
1 finding from 1 review
Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).
1 finding from 1 review
Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).
1 finding from 1 review
Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Success of prosthetic rehabilitation (preference) (1 day) · adults over the age of 50 with a unilateral transfemoral amputation
1 finding from 1 review
Intervention not reported
Adverse effects (1 day) · adults over the age of 50 with a unilateral transfemoral amputation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoxaemia · critically ill adult patients with unilateral lung disease
1 finding from 1 review
Global indicators of tissue oxygenation impairment Arterial‐venous oxygen content difference (C(a‐v)O2) ‐ not reported · critically ill adult patients with unilateral lung disease
1 finding from 1 review
Split renal function (SRF; · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction
1 finding from 1 review
Drainage pattern ( · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction
1 finding from 1 review
Upper urinary tract dilatation ( · newborns and infants < 2 years of age with unilateral ureteric‐pelvic junction obstruction
1 finding from 1 review